Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab

Tiziana Life Sciences announced positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for treating non-active secondary progressive multiple sclerosis (na-SPMS). The 50 μg dose met the primary endpoint with statistically significant reduction in microglial activation on TSPO PET imaging (p=0.0168) and showed clinically meaningful improvements in fatigue scores. Results were consistent with longer-term data from an expanded access program treating up to 14 patients for up to three years, with favorable safety profile and no anti-drug antibodies detected.